Canaccord analyst Kyle Mikson raised the firm’s price target on Grail (GRAL) to $105 from $85 and keeps a Buy rating on the shares. The firm target increase is driven by significant progress/plans to expand adoption levels (and reimbursement) for the Galleri multi-cancer early detection (MCED) test.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRAL:
- Grail price target raised to $85 from $38 at Morgan Stanley
- Grail Inc. Navigates Global Trade Challenges Amid Tariffs and Regulatory Hurdles
- Balanced Hold Rating on GRAIL Inc: Navigating Potential and Risks of Galleri’s Multi-Cancer Detection Test
- GRAIL Inc Announces $300M Equity Distribution Agreement
- Grail Inc. Earnings Call: Growth Amid Challenges